Dynavax Technologies (NASDAQ:DVAX) Rating Reiterated by HC Wainwright

Share on StockTwits

Dynavax Technologies (NASDAQ:DVAX)‘s stock had its “buy” rating reiterated by HC Wainwright in a report issued on Thursday, AnalystRatings.com reports.

A number of other equities research analysts have also issued reports on the company. Zacks Investment Research lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, October 15th. BidaskClub raised Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Thursday, October 24th. William Blair reaffirmed a “buy” rating on shares of Dynavax Technologies in a research report on Friday, August 16th. ValuEngine upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Cantor Fitzgerald upgraded Dynavax Technologies from a “neutral” rating to an “overweight” rating and set a $20.00 price target on the stock in a report on Wednesday, July 10th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Dynavax Technologies currently has a consensus rating of “Buy” and an average price target of $12.63.

NASDAQ:DVAX traded up $0.19 during midday trading on Thursday, reaching $5.26. 1,426,300 shares of the company traded hands, compared to its average volume of 1,330,133. The company has a fifty day moving average price of $4.39 and a 200 day moving average price of $4.54. The firm has a market capitalization of $349.23 million, a price-to-earnings ratio of -2.06 and a beta of 0.50. The company has a debt-to-equity ratio of 19.95, a current ratio of 4.30 and a quick ratio of 3.47. Dynavax Technologies has a twelve month low of $2.60 and a twelve month high of $12.77.

Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.10). The company had revenue of $10.58 million for the quarter, compared to analyst estimates of $10.31 million. Dynavax Technologies had a negative return on equity of 304.71% and a negative net margin of 781.10%. The firm’s revenue for the quarter was up 624.7% on a year-over-year basis. During the same period last year, the firm earned ($0.65) earnings per share. On average, equities research analysts forecast that Dynavax Technologies will post -1.93 earnings per share for the current fiscal year.

In other Dynavax Technologies news, Director Francis Cano purchased 16,667 shares of the stock in a transaction dated Monday, August 12th. The shares were acquired at an average price of $3.00 per share, for a total transaction of $50,001.00. Following the completion of the acquisition, the director now owns 118,484 shares of the company’s stock, valued at approximately $355,452. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.90% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. California Public Employees Retirement System grew its holdings in shares of Dynavax Technologies by 31.1% during the third quarter. California Public Employees Retirement System now owns 59,800 shares of the biopharmaceutical company’s stock valued at $214,000 after buying an additional 14,200 shares in the last quarter. Commonwealth Equity Services LLC grew its stake in Dynavax Technologies by 15.1% in the third quarter. Commonwealth Equity Services LLC now owns 30,034 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 3,950 shares in the last quarter. Gables Capital Management Inc. grew its stake in Dynavax Technologies by 6.7% in the third quarter. Gables Capital Management Inc. now owns 64,050 shares of the biopharmaceutical company’s stock valued at $231,000 after purchasing an additional 4,000 shares in the last quarter. Chicago Capital LLC grew its stake in Dynavax Technologies by 49.1% in the third quarter. Chicago Capital LLC now owns 4,380,216 shares of the biopharmaceutical company’s stock valued at $15,659,000 after purchasing an additional 1,442,950 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in Dynavax Technologies by 11.2% in the third quarter. Rhumbline Advisers now owns 95,722 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 9,670 shares in the last quarter. Institutional investors and hedge funds own 83.08% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

See Also: What is Blockchain?

Analyst Recommendations for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.